Minoryx successfully completes phase 1 clinical trial for lead candidate MIN-102 Blog Post

Minoryx Therapeutics – a drug development company specialized in the discovery and development of new drugs for orphan diseases, which has R& D laboratories at the Barcelona Science Park– announces that it has successfully completed its phase 1 trial with its lead compound MIN-102 targeting X-linked adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need.

 

Samuel receives the Catalonian National Research Award for Young Talent Blog Post

Yesterday IBEC group leader and ICREA research professor Samuel Sánchez at PCB, received the Catalonian National Research Award for Young Talent from the Catalan Government and the Catalan Foundation for Research and Innovation (FCRI).This prestigious honour and cash prize of €10,000 aims to encourage and acknowledge young researchers whose work and research has stood out during their professional career.

 

The AECC supports cancer research at IRB Barcelona Blog Post

Today, Jelena Urosevic and Carles Barceló, postdoctoral fellows at the Institute for Research in Biomedicine (IRB Barcelona) at the Barcelona Science Park, will officially be presented with funding over 5 years from the Asociación Española Contra el Cáncer (AECC) for their respective research projects on colon cancer. To date, IRB Barcelona has secured AECC funding for eight cancer projects.

 

The FBG receives € 150,000 from the AECC for childhood cancer research Blog Post

The project on neuroblastoma led by Elisa Martí Gorostiza, researcher at the Institute of Molecular Biology of Barcelona (IBMB-CSIC), based at PCB, and the Catalan Biotechnology Reference Network (XRB), has received one of the three grants for research projects on childhood cancer funded by the Spanish Association Against Cancer (AECC). The € 150,000 grant, obtained with the collaboration of the XRB, will be managed by the Bosch i Gimpera Foundation (FBG).

 

CataloniaBio grants the ‘BioSuccess of the Year’ award to STAT-Diagnostica Blog Post

The Catalan Association of Biotechnology Companies (CataloniaBio) has recognized Stat-Diagnostica –founded in 2010 at the Barcelona Science Park by Jordi Carrera and Rafael Bru– with the ‘Biosuccess of the Year’ Award. The prize giving ceremony was held yesterday at the Museu Maritimo of Barcelona under his winter networking event CataloniaBio Gala Dinner, a yearly meeting organised by this business association with the aim of enhancing scientific-business cooperation in Catalonia in the field of life sciences and health.

 

Dr Thomas Högberg to head up Mind the Byte office in Scandinavia Blog Post

Mind the Byte, located at the Barcelona Science Park, continues to reinforce its international presence. To this end, Thomas Högberg is joining the company as Business Development Director Scandinavia and Senior Advisor in order to consolidate computational design services in one of the most important pharmaceutical and biotechnology markets in Europe. He will carry out these responsibilities from the company’s offices at the Copenhagen Bio Science Park (COBIS).

 

Researchers find a gene that causes Opitz C syndrome in the only patient diagnosed in Catalonia Blog Post

A team led by the professors Daniel Grinberg and Susana Balcells, from the Institute of Biomedicine of the University of Barcelona (IBUB) at the Barcelona Science Park has identified a gene that causes the Opitz C syndrome in the only patient in Catalonia diagnosed with this genetic disease  which, so far, does not offer treatment possibilities, prenatal diagnosis or genetic counseling. This new scientific advance is a first step to discover the genetic bases of this congenital disease, that causes severe disabilities in patients and has been diagnosed in three people in the Iberian Peninsula, and sixty people in the world.  

 

Pangea Oncology, the first laboratory accredited in Spain to perform liquid biopsy for cancer treatment Blog Post

Pangaea Oncology –located at the Dexeus University Hospital and associated company of PCB – has been the first laboratory to be accredited in Spain for the determination of oncological biomarkers in blood (liquid biopsy) by the norm UNE-EN ISO 15189. This laboratory has great experience in the field of oncology, and was the first to be accredite in 2009 for the analysis in tissue of mutations in genes related to tumor processes, specifically in lung cancer. The result of these analyzes allows to predict the response to certain drugs and to apply personalized medicine to patients.

 

The V International Academic Symposium of IEB analyses the challenges of energy economics Blog Post

Yesterday, February 7, the V International Symposium of the Barcelona Institute of Economics (IEB) of the UB on the challenges in the energy sector took place at he Barcelona Science Park. The previous day, the Foundation for Energy and Environmental Sustainability (Funseam), which analyzes and shares the results of the research of the Chair of Energy Sustainability of the UB, had also organized its V International Symposium at PCB with the participation from public officers and businesspeople from the main firms of this sector. 

 

Researchers find a new key target for the treatment of prostate cancer Blog Post

A team led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) –at the Barcelona Science Park– and the Research Institute of the Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau) shows for the first time, the three-dimensional structure of the homodimeric androgen receptor ligand-binding domain, a structure that eluded researchers for years. This new structure of the nuclear receptor allows explaining more than forty mutations related to prostate cancer, one of the most common worldwide and especially in Catalonia, as well as known developing disorders.